Search clinical trials for: CD56

Total 29 results

Asmaa Hassan mohamed Abdel Mawjoud

Recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Hematologic Malignancies

Egypt
Yu Medical Garden

Unknown

A Single-Arm Study Evaluating the Efficacy of Liquid Acupuncture Therapeutics in Chronic Hepatitis B (CHB)

Liver Diseases | Virus Diseases | Hepatitis | Hepatitis B, Chronic | Diffuse Hepatic Disease
GlaxoSmithKline

Completed

Trial With Rhinitic Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber

Rhinitis, Allergic, Seasonal | Seasonal Allergic Rhinitis

Austria
BioMAS Ltd

Completed

Safety and Efficacy Study to Test Topical AS101 for External Genital Warts

Condyloma Acuminata | Wart; External Genital Organs

Israel
Glaxo Wellcome

Unknown

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

HIV Infections

United States
Assiut University

Unknown

Prognostic Value of CD Markers in Immune Thrombocytopenic Purpura

Immune Thrombocytopenia
Shenzhen Geno-Immune Medical Institute

Unknown

Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

GD2/CD56 Bi-specific CAR-T Cell Therapy

Malignant Disease

China
Ain Shams University

Completed

Are Uterine Natural Killer Cells Involved in the Initiation of Preterm Labor ?

Preterm Labour
Assiut University

Unknown

Cd11b and Cd56 as Prognostic Markers in Acute Myeloid Leukemia

Adult Acute Myeloid Leukemia
The Affiliated Hospital of Xuzhou Medical University

Recruiting

Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia

NK-Cell Leukemia | Extranodal NK T Cell Lymphoma

China
David Rizzieri, MD

Completed

Safety Trial of NK Cell DLI 3-5/6 Family Member Following Nonmyeloablative ASCT

Lymphoma

United States
Shenzhen Geno-Immune Medical Institute
Yunnan Cancer Hospital; Zhujiang Hospital, Southern Medical University, Guangzhou...

Unknown

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Assiut University

Not yet recruiting

Immune Markers in Pediatric ITP on Second Line Therapy

ITP - Immune Thrombocytopenia
Imperial College London

Withdrawn

CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplant | Haematological Malignancies | CD56+CD3- NK Cells

United Kingdom
Zhujiang Hospital
The Third Affiliated Hospital of Southern Medical University; Sun Yat-Sen Memorial... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma (MM)

Relapsed/Refractory Multiple Myeloma(MM)

China
David Rizzieri, MD

Completed

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

Lymphoma

United States
University Hospital, Basel, Switzerland

Completed

NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)

Lymphoma | Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Neuroblastoma | Rhabdomyosarcoma

Switzerland, Germany
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University

Recruiting

Universal CAR-T Cells Targeting Multiple Myeloma

Multiple Myeloma in Remission

China
Charite University, Berlin, Germany
University of Leipzig

Unknown

Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

Acute Myeloid Leukemias | Advanced Hematological Malignancies | Indication for Allogeneic Stem Cell Transplantation | no HLA-identical Donor Available

Germany
Zhujiang Hospital
Nanfang Hospital of Southern Medical University; The Third Affiliated Hospital... and other collaborators

Terminated

CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia (AML)

Relapsed/Refractory Acute Myeloid Leukemia(AML)

China
Assiut University

Not yet recruiting

Clinical Characters and Outcome of Acute Myeloid Leukemia Patients on Correlation to CD200 and CD56 Expression

Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Miltenyi Biomedicine GmbH

Withdrawn

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission

Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
ImmunoGen, Inc.

Completed

An Open-label Phase II Study of Lorvotuzumab Mertansine

Leukemia

United States
Miltenyi Biotec B.V. & Co. KG
University of Chicago; Ohio State University; Masonic Cancer Center, University...

Terminated

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

Acute Myelogenous Leukemia

United States
Technische Universität Dresden
German Research Foundation

Terminated

Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML (HINKL)

Acute Myeloid Leukemia

Germany
Cellectis S.A.

Terminated

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN (ABC123)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Noah Merin
Teva Branded Pharmaceutical Products R&D, Inc.; Miltenyi Biomedicine GmbH

Active, not recruiting

Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

Lymphoma | Multiple Myeloma | Hodgkin Lymphoma | Chronic Lymphocytic Leukemia | CLL

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies

Acute Myeloid Leukemia | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Chronic Myelomonocytic Leukemia | Acute Erythroid Leukemia | Acute Megakaryoblastic Leukemia | Myelodysplastic Syndrome | High Risk Myelodysplastic Syndrome | Blast Phase Chronic Myelogenous Leukemia,... and other conditions

United States

Search clinical trials for: CD56

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in India

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations